BAM15: A Novel Mitochondrial Uncoupler with Therapeutic Potential

Abstract

BAM15 is a newly identified mitochondrial protonophore that uncouples oxidative phosphorylation without depolarizing the plasma membrane. This unique property positions BAM15 as a promising candidate for treating various metabolic and inflammatory diseases. This article reviews the discovery, mechanism of action, and therapeutic applications of BAM15, highlighting its potential in managing obesity, diabetes, sepsis, and certain cancers.(Tocris Bioscience)

Introduction

Mitochondrial uncouplers disrupt the proton gradient across the mitochondrial inner membrane, leading to increased energy expenditure and reduced reactive oxygen species (ROS) production. Traditional uncouplers like 2,4-dinitrophenol (DNP) and FCCP have been limited by toxicity and off-target effects. BAM15 emerges as a novel uncoupler that overcomes these limitations, offering a safer alternative for therapeutic applications.(PubMed)

Discovery and Mechanism of Action

BAM15, chemically known as N^5,N^6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine, was identified through a screening of small molecule libraries aimed at finding mitochondrial uncouplers without plasma membrane depolarization effects . BAM15 facilitates proton transport across the mitochondrial inner membrane, dissipating the proton motive force and uncoupling oxidative phosphorylation. Unlike other uncouplers, BAM15 does not affect the plasma membrane potential, reducing cytotoxicity and enhancing its therapeutic index.(Tocris Bioscience, PubMed)

Therapeutic Applications

Obesity and Metabolic Disorders

BAM15 has demonstrated efficacy in preventing diet-induced obesity in mice. Treatment with BAM15 increased energy expenditure, improved insulin sensitivity, and enhanced glucose and lipid metabolism . In db/db mice, a model for type 2 diabetes, BAM15 improved glycemic control and reduced hepatic steatosis, effects comparable to calorie restriction but achieved without reducing food intake .(PubMed, ScienceDirect)

Sepsis and Acute Kidney Injury

In models of sepsis-induced acute kidney injury (AKI), BAM15 reduced mitochondrial ROS production and preserved mitochondrial function, leading to improved renal outcomes . These findings suggest BAM15’s potential in managing sepsis-related complications by targeting mitochondrial dysfunction.(Junior Chamber International)

Cancer Therapy

BAM15 has shown anti-cancer properties by inducing apoptosis and inhibiting proliferation in breast cancer and acute myeloid leukemia (AML) cells . Its ability to disrupt mitochondrial function selectively in cancer cells presents a novel approach to cancer treatment, potentially enhancing the efficacy of existing chemotherapies.(PubMed)

Safety and Pharmacokinetics

BAM15 exhibits a favorable safety profile, with minimal cytotoxicity and no significant plasma membrane depolarization . Its pharmacokinetic properties support its potential for clinical development, although further studies are needed to fully characterize its metabolism and long-term safety in humans.(PubMed)

Conclusion

BAM15 represents a promising mitochondrial uncoupler with therapeutic potential across various diseases characterized by mitochondrial dysfunction. Its unique mechanism of action and favorable safety profile warrant further investigation in clinical settings to fully realize its benefits in human health.

References

1. Kenwood, B. M., et al. (2014). Identification of a novel mitochondrial uncoupler that does not depolarize the plasma membrane. Biochimica et Biophysica Acta (BBA) – Bioenergetics, 1837(10), 2010–2022.(PubMed)
2. Chamberlain, K. A., et al. (2020). BAM15-mediated mitochondrial uncoupling protects against obesity and improves glycemic control. Nature Communications, 11, 2397.(PubMed)
3. Krause, M. P., et al. (2023). Targeting negative energy balance with calorie restriction and mitochondrial uncoupling in db/db mice. Molecular Metabolism, 63, 101547.(ScienceDirect)
4. Zhou, Y., et al. (2021). BAM15 treats mouse sepsis and kidney injury, linking mortality, mitochondrial DNA, tubule damage, and neutrophils. JCI Insight, 6(9), e152401.(Junior Chamber International)
5. Zhang, Y., et al. (2022). The new mitochondrial uncoupler BAM15 induces ROS production for treatment of acute myeloid leukemia. Biochemical and Biophysical Research Communications, 603, 1–7.(PubMed)
6. Krause, M. P., et al. (2021). Breast cancer growth and proliferation is suppressed by the mitochondrial targeted furazano[3,4-b]pyrazine BAM15. Cancer & Metabolism, 9(1), 10.(BioMed Central)

---

Note: This article is a synthesized summary based on current research findings on BAM15. For detailed information and experimental data, refer to the original publications cited above.